Risk factors for herpes simplex virus epithelial keratitis recurring during treatment of stromal keratitis or iridocyclitis

K. R. Wilhelmus, C. R. Dawson, B. A. Barron, P. Bacchetti, L. Gee, D. B. Jones, H. E. Kaufman, J. Sugar, R. A. Hyndiuk, P. R. Laibson, R. D. Stulting, Penny Asbell

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Aims - Possible risk factors were evaluated for herpes simplex virus (HSV) epithelial keratitis in patients with stromal keratouveitis. Methods - The study population included 260 patients who had active stromal keratitis and/or iridocyclitis without epithelial disease and who were enrolled in one of three clinical trials of the Herpetic Eye Disease Study. Study treatment involved a 10 week course of topical placebo, topical prednisolone phosphate, or topical prednisolone phosphate with oral acyclovir. All groups received topical trifluridine four times daily for 3 weeks then twice daily for another 7 weeks. Patients were examined for HSV epithelial keratitis for 16 weeks. Results - Dendritic or geographic epithelial keratitis occurred in 12 (4.6%) study patients. Adverse effects attributable to trifluridine prophylaxis were acute allergic blepharoconjunctivitis in 10 (3.8%) study patients and corneal epithelial erosions in 11 (4.2%) study patients. No significant difference in the occurrence of HSV epithelial keratitis was found among the study treatment groups: one (2.0%) of 49 topical placebo treated patients, nine (6.5%) of 138 patients treated with topical corticosteroids without acyclovir, and two (2.7%) of 73 patients treated with topical corticosteroids and oral acyclovir. Univariate exponential models suggested that patients with a history of previous HSV epithelial keratitis and non-white patients were more likely to develop HSV epithelial keratitis during treatment of stromal keratouveitis. Conclusion - Individuals with prior HSV epithelial keratitis and certain ethnic groups may have a higher rate of recurrent epithelial keratitis during the acute treatment of HSV stromal keratouveitis.

Original languageEnglish (US)
Pages (from-to)969-972
Number of pages4
JournalBritish Journal of Ophthalmology
Volume80
Issue number11
DOIs
StatePublished - Jan 1 1996

Fingerprint

Iridocyclitis
Keratitis
Simplexvirus
Acyclovir
Trifluridine
Therapeutics
Adrenal Cortex Hormones
Placebos
Eye Diseases
Ethnic Groups

All Science Journal Classification (ASJC) codes

  • Ophthalmology
  • Sensory Systems
  • Cellular and Molecular Neuroscience

Cite this

Risk factors for herpes simplex virus epithelial keratitis recurring during treatment of stromal keratitis or iridocyclitis. / Wilhelmus, K. R.; Dawson, C. R.; Barron, B. A.; Bacchetti, P.; Gee, L.; Jones, D. B.; Kaufman, H. E.; Sugar, J.; Hyndiuk, R. A.; Laibson, P. R.; Stulting, R. D.; Asbell, Penny.

In: British Journal of Ophthalmology, Vol. 80, No. 11, 01.01.1996, p. 969-972.

Research output: Contribution to journalArticle

Wilhelmus, KR, Dawson, CR, Barron, BA, Bacchetti, P, Gee, L, Jones, DB, Kaufman, HE, Sugar, J, Hyndiuk, RA, Laibson, PR, Stulting, RD & Asbell, P 1996, 'Risk factors for herpes simplex virus epithelial keratitis recurring during treatment of stromal keratitis or iridocyclitis', British Journal of Ophthalmology, vol. 80, no. 11, pp. 969-972. https://doi.org/10.1136/bjo.80.11.969
Wilhelmus, K. R. ; Dawson, C. R. ; Barron, B. A. ; Bacchetti, P. ; Gee, L. ; Jones, D. B. ; Kaufman, H. E. ; Sugar, J. ; Hyndiuk, R. A. ; Laibson, P. R. ; Stulting, R. D. ; Asbell, Penny. / Risk factors for herpes simplex virus epithelial keratitis recurring during treatment of stromal keratitis or iridocyclitis. In: British Journal of Ophthalmology. 1996 ; Vol. 80, No. 11. pp. 969-972.
@article{01311555181343b59deb67901b54e97a,
title = "Risk factors for herpes simplex virus epithelial keratitis recurring during treatment of stromal keratitis or iridocyclitis",
abstract = "Aims - Possible risk factors were evaluated for herpes simplex virus (HSV) epithelial keratitis in patients with stromal keratouveitis. Methods - The study population included 260 patients who had active stromal keratitis and/or iridocyclitis without epithelial disease and who were enrolled in one of three clinical trials of the Herpetic Eye Disease Study. Study treatment involved a 10 week course of topical placebo, topical prednisolone phosphate, or topical prednisolone phosphate with oral acyclovir. All groups received topical trifluridine four times daily for 3 weeks then twice daily for another 7 weeks. Patients were examined for HSV epithelial keratitis for 16 weeks. Results - Dendritic or geographic epithelial keratitis occurred in 12 (4.6{\%}) study patients. Adverse effects attributable to trifluridine prophylaxis were acute allergic blepharoconjunctivitis in 10 (3.8{\%}) study patients and corneal epithelial erosions in 11 (4.2{\%}) study patients. No significant difference in the occurrence of HSV epithelial keratitis was found among the study treatment groups: one (2.0{\%}) of 49 topical placebo treated patients, nine (6.5{\%}) of 138 patients treated with topical corticosteroids without acyclovir, and two (2.7{\%}) of 73 patients treated with topical corticosteroids and oral acyclovir. Univariate exponential models suggested that patients with a history of previous HSV epithelial keratitis and non-white patients were more likely to develop HSV epithelial keratitis during treatment of stromal keratouveitis. Conclusion - Individuals with prior HSV epithelial keratitis and certain ethnic groups may have a higher rate of recurrent epithelial keratitis during the acute treatment of HSV stromal keratouveitis.",
author = "Wilhelmus, {K. R.} and Dawson, {C. R.} and Barron, {B. A.} and P. Bacchetti and L. Gee and Jones, {D. B.} and Kaufman, {H. E.} and J. Sugar and Hyndiuk, {R. A.} and Laibson, {P. R.} and Stulting, {R. D.} and Penny Asbell",
year = "1996",
month = "1",
day = "1",
doi = "10.1136/bjo.80.11.969",
language = "English (US)",
volume = "80",
pages = "969--972",
journal = "British Journal of Ophthalmology",
issn = "0007-1161",
publisher = "BMJ Publishing Group",
number = "11",

}

TY - JOUR

T1 - Risk factors for herpes simplex virus epithelial keratitis recurring during treatment of stromal keratitis or iridocyclitis

AU - Wilhelmus, K. R.

AU - Dawson, C. R.

AU - Barron, B. A.

AU - Bacchetti, P.

AU - Gee, L.

AU - Jones, D. B.

AU - Kaufman, H. E.

AU - Sugar, J.

AU - Hyndiuk, R. A.

AU - Laibson, P. R.

AU - Stulting, R. D.

AU - Asbell, Penny

PY - 1996/1/1

Y1 - 1996/1/1

N2 - Aims - Possible risk factors were evaluated for herpes simplex virus (HSV) epithelial keratitis in patients with stromal keratouveitis. Methods - The study population included 260 patients who had active stromal keratitis and/or iridocyclitis without epithelial disease and who were enrolled in one of three clinical trials of the Herpetic Eye Disease Study. Study treatment involved a 10 week course of topical placebo, topical prednisolone phosphate, or topical prednisolone phosphate with oral acyclovir. All groups received topical trifluridine four times daily for 3 weeks then twice daily for another 7 weeks. Patients were examined for HSV epithelial keratitis for 16 weeks. Results - Dendritic or geographic epithelial keratitis occurred in 12 (4.6%) study patients. Adverse effects attributable to trifluridine prophylaxis were acute allergic blepharoconjunctivitis in 10 (3.8%) study patients and corneal epithelial erosions in 11 (4.2%) study patients. No significant difference in the occurrence of HSV epithelial keratitis was found among the study treatment groups: one (2.0%) of 49 topical placebo treated patients, nine (6.5%) of 138 patients treated with topical corticosteroids without acyclovir, and two (2.7%) of 73 patients treated with topical corticosteroids and oral acyclovir. Univariate exponential models suggested that patients with a history of previous HSV epithelial keratitis and non-white patients were more likely to develop HSV epithelial keratitis during treatment of stromal keratouveitis. Conclusion - Individuals with prior HSV epithelial keratitis and certain ethnic groups may have a higher rate of recurrent epithelial keratitis during the acute treatment of HSV stromal keratouveitis.

AB - Aims - Possible risk factors were evaluated for herpes simplex virus (HSV) epithelial keratitis in patients with stromal keratouveitis. Methods - The study population included 260 patients who had active stromal keratitis and/or iridocyclitis without epithelial disease and who were enrolled in one of three clinical trials of the Herpetic Eye Disease Study. Study treatment involved a 10 week course of topical placebo, topical prednisolone phosphate, or topical prednisolone phosphate with oral acyclovir. All groups received topical trifluridine four times daily for 3 weeks then twice daily for another 7 weeks. Patients were examined for HSV epithelial keratitis for 16 weeks. Results - Dendritic or geographic epithelial keratitis occurred in 12 (4.6%) study patients. Adverse effects attributable to trifluridine prophylaxis were acute allergic blepharoconjunctivitis in 10 (3.8%) study patients and corneal epithelial erosions in 11 (4.2%) study patients. No significant difference in the occurrence of HSV epithelial keratitis was found among the study treatment groups: one (2.0%) of 49 topical placebo treated patients, nine (6.5%) of 138 patients treated with topical corticosteroids without acyclovir, and two (2.7%) of 73 patients treated with topical corticosteroids and oral acyclovir. Univariate exponential models suggested that patients with a history of previous HSV epithelial keratitis and non-white patients were more likely to develop HSV epithelial keratitis during treatment of stromal keratouveitis. Conclusion - Individuals with prior HSV epithelial keratitis and certain ethnic groups may have a higher rate of recurrent epithelial keratitis during the acute treatment of HSV stromal keratouveitis.

UR - http://www.scopus.com/inward/record.url?scp=0029850568&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029850568&partnerID=8YFLogxK

U2 - 10.1136/bjo.80.11.969

DO - 10.1136/bjo.80.11.969

M3 - Article

VL - 80

SP - 969

EP - 972

JO - British Journal of Ophthalmology

JF - British Journal of Ophthalmology

SN - 0007-1161

IS - 11

ER -